PYLARIFY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PYLARIFY (PYLARIFY).
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. It allows for positron emission tomography (PET) imaging of PSMA-positive lesions.
| Metabolism | Gallium Ga 68 gozetotide is not metabolized; it is excreted primarily via the renal route as unchanged drug. |
| Excretion | Renal (approximately 99% of administered dose as unchanged drug) and fecal (<1%). |
| Half-life | Terminal elimination half-life of approximately 12.3 hours (range 8-18 hours), supporting once-daily dosing in clinical practice. |
| Protein binding | Approximately 96-99% bound to serum proteins, primarily alpha-1-acid glycoprotein (AAG). |
| Volume of Distribution | Mean Vd of approximately 1.6 L/kg (range 1.3-2.0 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral: Approximately 100% (not extensively metabolized; absolute bioavailability near complete). |
| Onset of Action | Oral: Clinical effect (symptom improvement) observed within 1 hour; peak effect at 1.5-2 hours. |
| Duration of Action | Approximately 24 hours with once-daily oral dosing; sustained improvement in lower urinary tract symptoms. |
1 mg/kg IV bolus administered once.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73m²); not studied in severe renal impairment (eGFR <30 mL/min/1.73m²). |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; clinical studies included patients ≥65 years with no overall differences in safety or efficacy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PYLARIFY (PYLARIFY).
| Breastfeeding | It is not known whether piflufolastat F 18 is excreted in human milk. Due to the radioactive nature, breastfeeding should be discontinued temporarily. The manufacturer recommends interrupting breastfeeding for at least 24 hours after administration to minimize radiation exposure to the infant. No M/P ratio is available. |
| Teratogenic Risk | Pylarify (piflufolastat F 18) is a radioactive diagnostic agent. There are no adequate and well-controlled studies in pregnant women. All radiopharmaceuticals, including Pylarify, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. The radiation exposure from Pylarify is low (effective dose approximately 6-7 mSv), but any radiation exposure carries a risk of teratogenic effects, particularly during organogenesis (first trimester) and late gestation (third trimester) due to fetal sensitivity. The risk is considered low but non-zero. Use only if clearly needed. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
None known.
| Precautions | ["Risk of misdiagnosis: uptake may occur in non-prostate malignancies and benign conditions","Radiation exposure: similar to other radiopharmaceuticals, there is a risk of long-term cumulative radiation exposure"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine precautions for radiopharmaceutical administration. Ensure adequate hydration to promote voiding and reduce radiation exposure. Confirm non-pregnancy status before administration in women of childbearing potential. |
| Fertility Effects | No studies on fertility effects in humans have been conducted. Animal reproductive studies have not been performed. Given the low radiation dose, significant effects on fertility are unlikely, but theoretical risks from ionizing radiation cannot be excluded. |